恒康医疗集团股份有限公司 2014 年第三季度报告正文 证券代码：002219 证券简称：恒康医疗 公告编号：2014-113 恒康医疗集团股份有限公司 2014 年第三季度报告正文 1 恒康医疗集团股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人段志平、主管会计工作负责人唐书虎及会计机构负责人(会计主管人员)王中华声明：保证 季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,832,330,092.54 | 1,143,093,577.1 ...

恒康医疗集团股份有限公司 2014 年半年度报告全文 恒康医疗集团股份有限公司 2014 年半年度报告 2014-083 2014 年 08 月 1 恒康医疗集团股份有限公司 2014 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人段志平、主管会计工作负责人唐书虎及会计机构负责人(会计主 管人员)王中华声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 2014 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 19 | | 第五节 | 重要事项 24 | | 第六节 | 股份变动及股东情况 28 | | 第七节 | 优先股相关情况 28 | | 第八节 ...

恒康医疗集团股份有限公司 2014 年第一季度报告全文 恒康医疗集团股份有限公司 2014 年第一季度报告 2014 年 04 月 1 恒康医疗集团股份有限公司 2014 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人段志平、主管会计工作负责人唐书虎及会计机构负责人(会计主 管人员)王中华声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2014 年第一季度报告全文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减（%） | | 营业收入（元） | 175,313,420.22 | 166,522,691.59 | 5.28% | | 归属于上市公司 ...

Financial Performance - The company's operating revenue for Q1 2014 was ¥175,313,420.22, an increase of 5.28% compared to ¥166,522,691.59 in the same period last year[8] - Net profit attributable to shareholders reached ¥74,460,271.92, representing a significant increase of 48.23% from ¥50,232,055.59 year-on-year[8] - The net cash flow from operating activities decreased by 33.66% to ¥42,885,505.79, down from ¥64,644,693.24 in the previous year[8] - Total assets at the end of the reporting period were ¥1,345,829,597.08, reflecting a growth of 17.74% from ¥1,143,093,577.10 at the end of the previous year[8] - The weighted average return on equity increased to 9.1%, up from 8.25% in the same period last year, marking an improvement of 0.85%[8] Revenue Sources and Growth - The company reported a significant increase in revenue from toothpaste, health products, and medical services, contributing to the rise in net profit[16] - Accounts receivable increased by 35.74% to CNY 268,460,698.70, driven by revenue from toothpaste, health products, and traditional Chinese medicine[19] - Other receivables rose by 104.89% to CNY 95,855,645.67, due to a CNY 30 million prepayment for equity acquisition of Liao Yu Hospital[19] - Sales of the unique toothpaste series and health products have seen substantial growth following the establishment of market and pharmacy channels[27] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,152, with the top ten shareholders holding a combined 70.39% of the shares[11] - The largest shareholder, Que Wenbin, holds 51.51% of the shares, amounting to 317,604,000 shares, with 224,848,000 shares pledged[11] Acquisitions and Investments - The company acquired 100% equity of Qionglai Welfare Hospital for CNY 60 million, with CNY 30 million paid and the remainder contingent on performance[20][22] - The company signed an agreement to acquire 100% equity of Dalian Liao Yu Hospital for CNY 127.8 million, with legal procedures ongoing[22] - The company plans to establish a wholly-owned subsidiary in Gansu Province with an investment of CNY 20 million[23] Expenses and Cost Management - Management expenses increased by 116.06% to CNY 15,357,917.87, due to the addition of 4 hospitals and 2 new enterprises[19] - The company reported a significant decrease in sales expenses by 98.43% to CNY 646,868.75, due to a change in sales strategy[19] Future Outlook - The net profit attributable to shareholders for the first half of 2014 is expected to increase by 44% to 63%, ranging from 15,000 to 17,000 thousand yuan[27] - The net profit for the first half of 2013 was 10,407.49 thousand yuan, indicating significant growth in 2014[27] - The acquisition of new hospital businesses is anticipated to become a new profit growth point for the company[27] Compliance and Commitments - The actual controller has committed to avoiding competition in the same industry since July 20, 2007, and is currently fulfilling this commitment[26] - There are no unfulfilled commitments or specific reasons for non-compliance reported[26] Government Support - The company received government subsidies amounting to ¥100,000 during the reporting period[9] Financing Activities - Short-term loans increased by 63.33% to CNY 245,000,000.00, attributed to increased bank loans during the reporting period[19] - The company’s unallocated profits decreased by 65.52% to CNY 76,725,476.89, impacted by profit distribution and net profit changes[19] - The company’s cash flow from operating activities showed a significant increase in tax payments, reflecting higher profits during the reporting period[19]

Financial Performance - The company's operating revenue for 2013 was CNY 564,725,360.31, representing a 67.59% increase compared to CNY 336,964,448.10 in 2012[21] - The net profit attributable to shareholders for 2013 was CNY 169,827,048.01, a significant increase of 130.52% from CNY 73,672,375.13 in the previous year[21] - The net cash flow from operating activities reached CNY 158,400,972.07, up 91.52% from CNY 82,705,472.16 in 2012[21] - The basic earnings per share for 2013 was CNY 0.3879, reflecting a 126.18% increase from CNY 0.1715 in 2012[21] - Total assets at the end of 2013 amounted to CNY 1,143,093,577.10, a 31.53% increase from CNY 869,097,842.03 at the end of 2012[21] - The net assets attributable to shareholders increased to CNY 803,132,199.68, up 47.5% from CNY 544,478,071.67 in 2012[21] - The weighted average return on equity for 2013 was 24.93%, an increase from 14.44% in 2012[21] Business Expansion and Acquisitions - The company established four major business divisions, including pharmaceuticals, daily chemicals, health products, and medical services, to enhance market presence and operational efficiency[31] - The company acquired 85% of the revenue rights from Chengdu Ping An Hospital's oncology business and 100% equity of three other hospitals, expanding its footprint in the healthcare sector[35] - The company has made strategic acquisitions, including Sichuan Huaji Pharmaceutical Co. and Baishan Sanbaotang Biotechnology Co., to diversify its product offerings and enhance competitiveness in the healthcare market[71] - The company acquired 100% equity of three hospitals: Deyang Meihua Mingtian Hospital, Ziyang Jianshun Wang Health Checkup Hospital, and Pengxi Jianshun Wang Traditional Chinese Medicine (Orthopedics) Hospital for a total of 8,000,000 CNY, contributing a net profit of 702.27 CNY, which accounts for 4.14% of the total net profit[101] - The company also acquired 100% equity of Baishan Sanbaotang Biotechnology Co., Ltd. and Sichuan Huaji Pharmaceutical Co., Ltd., with the details disclosed on June 7, June 28, September 12, and November 7, 2013[101] Research and Development - Research and development investments increased by 10.43% year-on-year, focusing on modern pharmaceutical products and the independent development of the Du Yi Wei series[34] - The company is focusing on R&D for innovative products, including a new anti-tumor drug project (DYW101) that has completed cell line establishment and druggability verification[53] - The company has a strong product pipeline with 6 national pharmacopoeia varieties, 3 protected traditional Chinese medicine varieties, and 9 exclusive national varieties[53] Financial Management and Governance - The company has established a comprehensive corporate governance structure and internal control system to protect the rights of shareholders and creditors, ensuring timely and accurate information disclosure[87] - The company has maintained a 100% rate of signing labor contracts and participating in social insurance for employees, emphasizing talent development and career planning[87] - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders[166] - The company has established effective performance evaluation and incentive mechanisms for directors, supervisors, and senior management, enhancing team efficiency, although no equity incentive measures have been implemented yet[166] Employee and Management Structure - The total number of employees as of December 31, 2013, was 1,522, with 648 sales personnel accounting for 70.90% of the workforce[157] - The company has a total of 10 senior management personnel[149] - The company has a diverse employee professional structure, with 6.35% being technical personnel[158] - The company has appointed new board members, including Tang Can and Guo Kai, to enhance the board's functionality[155] Market Strategy and Future Plans - The company aims to expand its healthcare services through acquisitions and new establishments, enhancing its dual-driven model of pharmaceutical manufacturing and medical services[53] - The company plans to actively pursue mergers and acquisitions, particularly targeting oncology-related medical assets, to enhance its sustainable development capabilities[78] - The company plans to expand its medical services and aims to achieve a total scale of the health service industry exceeding 8 trillion yuan by 2020[76] Shareholder Engagement and Profit Distribution - The company has proposed a profit distribution plan for 2013, which includes a cash dividend of 1 yuan per 10 shares and a stock bonus of 4 shares per 10 shares, totaling 44.05 million yuan in cash dividends[84] - The cash dividend represents 20% of the total profit distribution amount, aligning with the company's policy to maintain a minimum cash dividend ratio of 20% during its growth phase[85] - The company actively engages with investors through various communication channels, enhancing transparency and trust[87] Financial Health and Asset Management - The company reported a total asset of RMB 1,143,093,577.10 as of December 31, 2013, an increase from RMB 869,097,842.03 at the beginning of the year, reflecting a growth of approximately 31.5%[199] - The company's cash and cash equivalents decreased to RMB 110,824,249.42 from RMB 300,717,482.21, representing a decline of about 63.2%[198] - Accounts receivable increased significantly to RMB 197,780,859.35 from RMB 113,058,684.43, marking an increase of approximately 75.1%[198] - The company received a standard unqualified audit opinion from Ruihua Certified Public Accountants, confirming the fair presentation of its financial statements[191]